Loading…
MDCX
Medicus Pharma Ltd.
NASDAQ· Healthcare· Drug Manufacturers - General· CUSIP 58471K202
$0.26-3.77%Price as of Aug 29, 18:49 UTC · updated once a day, after the close
Key metrics
- Market cap
- $16.28M
- P/E
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- —
- Payout
- —
- EPS
- -$2.26
- ROE
- -7446.11%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- -0.48
- 52-week high
- $3.05
- 52-week low
- $0.24
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -94.3% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $1.53 | $2.43 | |
| P/B | — | — | 9.2x |
| EPS | -$2.74 | -$1.16 | |
| ROE | — | — | -355.87% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SCNXScienture Holdings, Inc. | $0.39 | — | 0.3x | — | -53.47% | $16.18M |
| ADILAdial Pharmaceuticals Inc | $5.60 | — | — | — | -2011.64% | $16.43M |
| NMTCNEUROONE MEDICAL TECHNOLOGIES Corp | $1.77 | — | 4.1x | — | -124.66% | $16.12M |
| PLURPluri Inc. | $1.53 |
About the company
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome. The company was formerly known as Interactive Capital Partners Corporation and changed its name to Medicus Pharma Ltd. in September 2023. The company was incorporated in 2008 and is headquartered in West Conshohocken, Pennsylvania.
- 16
- West Conshohocken, United States
Company description provided by Yahoo Finance.